about
Systemic delivery of oncolytic viruses: hopes and hurdlesPEGylated Adenoviruses: From Mice to MonkeysPreclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model systemCombined bacterial and viral treatment: a novel anticancer strategyDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsAntioxidant-based therapies for angiotensin II-associated cardiovascular diseasesTissue engineering tools for modulation of the immune responseSPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131IEfficient uptake of blood-borne BK and JC polyomavirus-like particles in endothelial cells of liver sinusoids and renal vasa rectaRapid and efficient clearance of blood-borne virus by liver sinusoidal endotheliumChitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cellsDevelopment of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In VivoDesigner gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferSystemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerCombining Oncolytic Virotherapy with p53 Tumor Suppressor Gene TherapyPreclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic AdenovirusRecombinant adeno-associated virus: efficient transduction of the rat VMH and clearance from blood.Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusRedundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase.Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactionsOncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration.Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectorsRecognition of virus infection and innate host responses to viral gene therapy vectors.Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse modelTreatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene.Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber.Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracersReplication properties of human adenovirus in vivo and in cultures of primary cells from different animal speciesClearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complementα-Galactosidase A expressed in the salivary glands partially corrects organ biochemical deficits in the fabry mouse through endocrine traffickingAdrenal gland infection by serotype 5 adenovirus requires coagulation factors.Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus
P2860
Q21284969-0A66855D-FBD8-47C2-B715-A3DEB858371BQ24635276-F3BE86FD-8BFF-466A-A415-E1E3E99C76C2Q25257352-5470C2E3-DB9F-40C9-8D83-E30B8D9F0B37Q26773180-2EDDCC7A-2FEC-4B54-8937-BBA19AD7715AQ26782083-CCEE4275-0E64-4509-9ADF-6AFB7510FF84Q27016563-C6E0103B-03A1-4171-98DE-1AB0D0D6FB37Q27023419-3DD8B4FC-9925-492A-9632-54F39AA66919Q27307734-479653B3-4535-4F39-86C3-B60DA1CB61C9Q27332309-B27C2A09-CC29-46E8-8456-4A4944C15AFAQ27348854-7C14EEC3-5BEC-4412-A5B3-416C9E33775DQ28475072-14798525-1B0D-4A5D-B558-48FDD161DB59Q28534124-969C6ADA-558E-4A03-BD3A-876D74B0D110Q33296224-B136DE1F-623E-4F2F-BD7E-6E9A88AC1FB6Q33385742-EF67AFF5-3C80-4955-95F5-EE9014B49497Q33434692-1E787D9C-8BEC-43A2-A3C0-60192D3D53ABQ33584756-7A85DA8D-8E02-4AA6-9DB6-2F8390601FBBQ33633277-B26667D7-007A-4923-9622-3EE1803A72E6Q33633287-B1E5184C-ECA9-4E49-AF15-28BDC91F8E9BQ33654870-AAD2138A-429B-444E-A3B6-2E1135932BABQ33690982-54119666-E923-45F1-BDB5-DA826831DFBAQ33713401-7E7F5014-E98D-47BA-B0AF-E37FDB0D8BC4Q33803963-A9DF8C33-8054-4467-8933-38D52377E976Q33812130-25EEF3A4-1663-4761-BD76-43BD95F21200Q33849565-8202F818-83BA-4D85-82D9-F0E7CD1C36A2Q33906116-986151D8-00EB-4061-8F49-8CDEA45C528FQ33978310-C0CAA68B-2FCA-40A1-A6CE-0A9836D693C7Q34057708-5BBCCB19-A325-4305-A233-D8FB1367A685Q34080884-22A0178B-708F-44FA-B9B5-CB3483B4A2EAQ34153735-0D7D9401-5809-4E4E-AEEC-DFB188BB5705Q34183436-12386909-4132-4369-90A5-E21966044208Q34194326-1E4BCC60-229F-4CD5-8893-FBF4B210642FQ34226587-0CE8647F-6F88-42CC-AD9D-4064140E98B4Q34310576-3A804928-BC9B-44C8-B234-C907F8D82074Q34470809-6E790301-A5B8-4DD3-9303-BF5612758320Q34480119-903A23A8-D7EB-4A70-A47A-825F7DF3B325Q34545667-640B0AA2-C206-471E-AF1C-52E4EEF9B619Q34597583-F4DE416D-9652-4C8B-8838-745619A67F2DQ34671627-6D8FEB04-7203-4C29-9683-4398545ACEC6Q34701038-CBABA13C-F2E0-4C15-A6AA-5BCF7D1AFF0CQ34975214-C420EDA1-9825-4E47-B0EB-CED27EE72124
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Blood clearance rates of adenovirus type 5 in mice.
@en
Blood clearance rates of adenovirus type 5 in mice.
@nl
type
label
Blood clearance rates of adenovirus type 5 in mice.
@en
Blood clearance rates of adenovirus type 5 in mice.
@nl
prefLabel
Blood clearance rates of adenovirus type 5 in mice.
@en
Blood clearance rates of adenovirus type 5 in mice.
@nl
P1476
Blood clearance rates of adenovirus type 5 in mice.
@en
P2093
P304
P356
10.1099/0022-1317-81-11-2605
P407
P577
2000-11-01T00:00:00Z